Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.
about
New vaccines: challenges of discoveryEmerging experience with meningococcal serogroup B protein vaccines.Recent Progress in the Prevention of Serogroup B Meningococcal Disease.Does post-implementation vaccine effectiveness data support pre-implementation predictions of 4CMenB utility?Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal.Enhanced protective antibody to a mutant meningococcal factor H-binding protein with low-factor H binding.Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci.Meningococcal serogroup B vaccines: Estimating breadth of coverage.Frequent capsule switching in 'ultra-virulent' meningococci - Are we ready for a serogroup B ST-11 complex outbreak?The next chapter for group B meningococcal vaccines.An unwanted guest: Neisseria meningitidis - carriage, risk for invasive disease and the impact of vaccination with insight on Italy incidence.Serum Bactericidal Antibody Responses of Students Immunized With a Meningococcal Serogroup B Vaccine in Response to an Outbreak on a University Campus.Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules.Meningococcal Antigen Typing System (MATS)-Based Neisseria meningitidis Serogroup B Coverage Prediction for the MenB-4C Vaccine in the United States.Commentary: Impact of meningococcal group B OMV vaccines, beyond their brief.4CMenB vaccine effectiveness: reasons for optimism.Challenges and opportunities for Meningococcal vaccination in the developing world.Cross-protection induced by VA-MENGOC-BC® vaccine.The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C.Distinct evolutionary patterns of Neisseria meningitidis serogroup B disease outbreaks at two universities in the USA.Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines.Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development.Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Isolated from 2009 to 2013 in the Republic of Ireland
P2860
Q26970823-0271F1F0-CEAC-4FFA-8EC6-F6E2EE091383Q30234958-E114298C-C599-4EE0-A166-A915366D13A7Q30235040-3EA634D9-3655-475B-9106-8D08F4499366Q30235138-AB934AFD-E35F-41CD-816C-75C9B0424529Q33620864-082A7C7F-36C2-435C-89BA-B7350883E0F6Q37277250-E710894D-EE8D-4E3F-89C8-483108F5E617Q37563627-4AB35B8A-3E5A-4F4C-92C2-EBB475F99119Q37669413-E897F767-1FE4-4C57-9593-64D8A17E02ABQ38674983-84F762A4-C608-42FB-8121-5BA48C81A43AQ38677309-6A71E2F9-1A43-4BE4-9F03-CF88F4253694Q38775024-4293B93D-7A88-42D0-9451-8B607B256002Q40172533-4AB75972-1151-4729-99AA-FBF833D3D920Q40178578-35B95FF0-8E22-48C7-82F9-E882FEC42D5DQ42678551-B5D78306-44BC-4441-BC10-605BE7EB7BD5Q45824896-78B55E03-39A3-4EA6-BF56-6CB35048E784Q46280467-DCA0BBA6-FA6D-456C-A8DB-29C78FB90861Q47352260-5CDED3C2-EDDE-4559-9AAF-B36D8CD52C5CQ49377063-B4782148-B445-4548-8D95-75DE4187247BQ50116274-C1080BF4-E1E7-49FA-A613-80198B90598AQ50922458-0FDE0656-F3E1-45E9-949F-860BD44A16C4Q52332492-45173425-E095-410A-8DF9-8EF29969B0B0Q54233532-6B8DECA1-E155-4286-A031-B420A663FBD3Q54255446-88135731-3E8A-4CB3-A0F7-664F39CB2013Q57970428-A07424A2-A6E2-48CD-926C-EAC810EFD69A
P2860
Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.
@en
Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.
@nl
type
label
Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.
@en
Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.
@nl
prefLabel
Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.
@en
Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.
@nl
P2093
P2860
P356
P1476
Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.
@en
P2093
Adel A F Mahmoud
Alexander Ploss
Brigitte L Heller
Jamie Findlow
Julian Wolfson
Nicole E Basta
Peter Johnsen
Robin Izzo
Sarah Hanna
Xilian Bai
P2860
P304
P356
10.1056/NEJMOA1514866
P407
P577
2016-07-01T00:00:00Z